Literature DB >> 16735714

Neoadjuvant therapy with bevacizumab.

Thomas Gruenberger, Birgit Gruenberger, Werner Scheithauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16735714     DOI： 10.1200/JCO.2005.05.2910

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

1.  [Bevacizumab (Avastin) related surgical complications: comment to Abbrederis K et al. (2007)].

Authors:  F Lordick; J R Siewert
Journal:  Chirurg       Date:  2008-04       Impact factor: 0.955

2.  Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation.

Authors:  P Starlinger; L Alidzanovic; D Schauer; T Maier; C Nemeth; B Perisanidis; D Tamandl; B Gruenberger; T Gruenberger; C Brostjan
Journal:  Br J Cancer       Date:  2012-07-31       Impact factor: 7.640

Review 3.  Angiogenesis in cancer: molecular mechanisms, clinical impact.

Authors:  M E Eichhorn; A Kleespies; M K Angele; K-W Jauch; C J Bruns
Journal:  Langenbecks Arch Surg       Date:  2007-02-16       Impact factor: 2.895

4.  Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases.

Authors:  Birgit Gruenberger; Werner Scheithauer; Robert Punzengruber; Christoph Zielinski; Dietmar Tamandl; Thomas Gruenberger
Journal:  BMC Cancer       Date:  2008-04-25       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.